Individual InvestorsBB Biotech AG
ISIN-No.: CH0038389992
YTD: -2.95%
Active share: 79.01
Anzahl Positionen: 23
New innovative drugs and technologies are powering sustainable momentum in the biotech sector
Focus on profitable companies and small and mid-cap companies with strong pipelines
Attractive dividend policy; Dividend payment of 5% p.a.
Indexed performance (as at: 21.07.2025)
Share price: CHF 32.50 (21.07.2025)
NAV: CHF 35.95 (21.07.2025)
Rolling performance (21.07.2025)
| Share Price | NAV | Benchmark | |
| 21.07.2024 - 21.07.2025 | -19.45% | -19.10% | -16.41% |
| 21.07.2023 - 21.07.2024 | -0.03% | 14.60% | 18.42% |
| 21.07.2022 - 21.07.2023 | -19.38% | -10.90% | -5.71% |
| 21.07.2021 - 21.07.2022 | -28.47% | -24.43% | -16.08% |
Annualized performance (21.07.2025)
| Share Price | NAV | Benchmark | |
| 1 year | -19.45% | -19.10% | -16.41% |
| 3 years | -13.41% | -6.17% | -2.33% |
| 5 years | -9.92% | -6.52% | -3.19% |
| 10 years | -1.45% | -2.29% | -0.68% |
| Since Inception p.a. | 9.27% | 9.57% | 8.32% |
Cumulative performance (21.07.2025)
| Share Price | NAV | Benchmark | |
| 1M | 9.43% | 3.47% | 2.59% |
| YTD | -2.95% | -10.29% | -9.66% |
| 1 year | -19.45% | -19.10% | -16.41% |
| 3 years | -35.08% | -17.40% | -6.83% |
| 5 years | -40.70% | -28.62% | -14.98% |
| 10 years | -13.63% | -20.70% | -6.56% |
| Since Inception | 1'561.33% | 1'710.26% | 1'158.81% |
Annual performance
| Share Price | NAV | Benchmark | |
| 2024 | -13.53% | 2.97% | 7.56% |
| 2023 | -18.15% | -7.39% | -4.79% |
| 2022 | -24.29% | -11.00% | -9.09% |
| 2021 | 8.34% | -11.45% | 2.98% |
Facts & Key figures
Investment Focus
BB Biotech actively invests worldwide in fast growing companies developing and marketing innovative biotech drugs. At least 90% of its shareholdings must be in listed companies, while always holding more than 50% of its assets in equity investments. Show moreShow less
Investment suitability & Risk
Low risk
High risk
General Information
| Investment Manager | Bellevue Asset Management AG |
| Custodian | Bank Julius Bär AG |
| Fund Administrator | Bellevue Asset Management AG |
| Auditor | Deloitte AG |
| Launch date | 09.11.1993 |
| Year end closing | 31. Dec |
| Management Fee | 1.10% |
| ISIN number | CH0038389992 |
| Valor number | 3838999 |
| Bloomberg | BION SW Equity |
| WKN | A0NFN3 |
Legal Information
| Legal form | Incorporate company |
| SFDR category | Article 8 |
Key data (30.06.2025, base currency CHF)
| Beta | 1.22 |
| Volatility | 28.78 |
| Tracking error | 13.43 |
| Active share | 79.01 |
| Correlation | 0.90 |
| Sharpe ratio | -0.02 |
| Information ratio | -0.04 |
| Jensen's alpha | -0.58 |
| No. of positions | 23 |
Portfolio as at 31.03.2025
Positions
Market capitalization
Breakdown by sector
Currency
Benefits & Risks
Benefits
- Unique opportunity for European investors to access the global biotech sector, a non-cyclical growth industry that is strongly supported by increasing demand, driven by demographic trends and life style changes.
- New innovative drugs and technologies are powering sustainable momentum in the biotech sector.
- Focus on a diversified portfolio of profitable companies as well as small and midcap companies with strong pipelines.
- Management Team with strong scientific and medical expertise. Renowned Board of Directors.
- Attractive dividend policy; Dividend payment of 5% p.a.
Risks
- BB Biotech actively invests in equities. Equities are subject to strong price fluctuations and so are also exposed to the risk of price losses.
- Biotech equities can be subject to sudden substantial price movements owning to market, sector or company factors.
- BB Biotech invests in foreign currencies, which means a corresponding degree of currency risk against the reference currency.
- The price investors pay or receive, like other listed shares, is determined by supply and demand and may be at a discount or premium to the underlying net asset value of the Company.
- BB Biotech may take a leverage of up to 15%, which may lead to even higher price movements compared to the underlying market.
Review / Outlook
In June we saw an increase in M&A activity in the biotech sector with the most notable being Sanofi’s announced acquisition of Blueprint Medicines for USD 9.5 bn. M&A activity in the biotech sector remains a strategic tool for large pharmaceutical companies to address the impending revenue gaps caused by expiring patents and significant sales declines. The industry still possesses near record-level of M&A firepower, with the capacity to facilitate transactions totalling multi-billions USD. Pharmaceutical companies continue to have appetite for consolidation and growth.
Please find below selected highlights in June from some of BB Biotech´s portfolio companies:
Scholar Rock (+22.1%, in USD) announced on June 18 positive results from the Phase II EMBRAZE proof-of-concept trial assessing apitegromab in combination with tirzepatide to preserve lean mass during tirzepatide-induced weight loss. The trial demonstrated that 30% of total weight loss with tirzepatide alone was due to lean mass loss. Apitegromab therapy (10 mg/kg) with tirzepatide preserved an additional 4.2 pounds (1.9 kilograms) or 54.9% (p=0.001) of lean mass compared to tirzepatide alone, leading to higher quality weight loss. Apitegromab with tirzepatide was generally well tolerated by participants.
Moderna (+3.9%, in USD) announced on June 12 that the FDA has approved mRESVIA® (mRNA-1345), the company's respiratory syncytial virus (RSV) vaccine, for the prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals 18-59 years of age who are at increased risk for disease. This approval expands the previous indication of mRESVIA, which was approved in May 2024 for adults aged 60 years and older.
Celldex (+2.9%, in USD) announced on June 12 new data demonstrating profound, sustained complete response and improved quality of life at 76 weeks, 7 months after the completion of dosing with barzolvolimab in chronic spontaneous urticaria (CSU), an immune-related condition driven by mast cell activation. Barzolvolimab specifically targets mast cells by binding the receptor tyrosine kinase KIT with high specificity and potently inhibiting its activity, which is required for mast cell function and survival.
Revolution Medicines (-6.6%, in USD) announced on June 24 that it has partnered with Royalty Pharma on USD 2 bn in flexible funding to support Revolution Medicines’ independent global development and commercialization strategy and operations. Revolution Medicines retains full strategic and executional control of product development and commercialization for its portfolio of RAS(ON) inhibitors in the US and internationally.
Dokumente
Show moreShow less
